| JV |
AVENTIS, IMMUNOGEN FORM CANCER DRUG JOINT VENTURE Aventis and ImmunoGen have entered into an agreement to jointly develop and market anticancer drugs. Under the deal, Aventis acquires global marketing rights to new products and three ImmunoGen products in early development: a treatment for blood cancer; one for solid tumors including breast, lung and prostate applications; and a new drug for B-cell blood cancers including nonHodgkin’s lymphoma |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |